Forbes J M & Co. LLP Has $1.22 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Forbes J M & Co. LLP cut its position in Eli Lilly and Company (NYSE:LLY) by 1.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,568 shares of the company’s stock after selling 25 shares during the period. Forbes J M & Co. LLP’s holdings in Eli Lilly and Company were worth $1,220,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LLY. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Eli Lilly and Company by 7.0% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 3,054 shares of the company’s stock worth $1,640,000 after acquiring an additional 200 shares during the period. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $36,000. Eagle Asset Management Inc. increased its stake in Eli Lilly and Company by 37.2% in the 3rd quarter. Eagle Asset Management Inc. now owns 21,274 shares of the company’s stock valued at $11,427,000 after buying an additional 5,772 shares during the last quarter. Jacobi Capital Management LLC increased its stake in Eli Lilly and Company by 7.7% in the 3rd quarter. Jacobi Capital Management LLC now owns 16,394 shares of the company’s stock valued at $8,805,000 after buying an additional 1,168 shares during the last quarter. Finally, GSB Wealth Management LLC increased its stake in Eli Lilly and Company by 10.3% in the 3rd quarter. GSB Wealth Management LLC now owns 800 shares of the company’s stock valued at $430,000 after buying an additional 75 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the transaction, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares in the company, valued at approximately $20,835,194.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of Eli Lilly and Company stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The disclosure for this sale can be found here. In the last ninety days, insiders sold 772,475 shares of company stock worth $656,838,859. 0.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Jefferies Financial Group lifted their price objective on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, June 17th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $803.50.

Eli Lilly and Company Price Performance

LLY stock opened at $883.88 on Monday. The company has a 50 day simple moving average of $798.59 and a 200 day simple moving average of $729.89. The stock has a market cap of $840.05 billion, a price-to-earnings ratio of 130.17, a P/E/G ratio of 1.93 and a beta of 0.36. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $905.45. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the firm posted $1.62 EPS. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.